Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissecting the biological heterogeneity of HER2-positive breast cancer

5 Aug 2021

Abstract excerpt

HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular subtypes can be identified in HER2+ tumors, with the HER2-enriched being the most frequent. Such subtypes do not differ much from their counterparts in HER2-negative disease, apart for the high expression of genes in/near the HER2 amplicon on chromosome 17....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34392185
DOI: 10.1016/j.breast.2021.07.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting the biological heterogeneity of HER2-positive breast cancerPMID 34392185Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

The Distinctive Nature of HER2-Positive Breast CancersSemantic proximity Read ↗

Associations of TILs and genomic alterations in HER2+ early breast cancer.Semantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Semantic proximity Read ↗

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive reviewSemantic proximity Read ↗

Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.